Reuters
Published Feb 15, 2023 04:52PM ET
Updated Feb 17, 2023 01:06PM ET
By Bhanvi Satija and Pratik Jain
(Reuters) -Emergent BioSolutions Inc's over-the-counter version of opioid overdose reversing drug received unanimous support from U.S. Food and Drug Administration's panel of advisers, sending shares of the contract drugmaker up nearly 16% after market.
The vote puts the naloxone-based treatment Narcan on track to potentially become the first opioid overdose drug to be sold OTC nationwide. Naloxone rapidly reverses or blocks the effects of an overdose, restoring normal respiration.
While some experts believe an eventual approval by the U.S. health regulator could make an impact on the overdose crisis, others have cautioned against prescription-free use of naloxone, citing the need for professional oversight.
However, most panelists emphasized that OTC use of the nasal spray was safe and proposed ways to improve its labeling, to avoid using the drug wrong.
Panelist Brian Bateman said there was room for improving the labeling, "but I think the evidence we saw today provides clear indications that the drug can be used without direction of the healthcare provider."
Advisers suggested that all five steps of administering the drug should be printed only on the back panel instead of across the back and side panels of the drug's packaging, which has led to confusion among consumers about the order of the steps to be followed.
Other suggestions were around including a separate 'quick-start' user guide and including pictograms for easier identification of different parts of the spray.
"The current prescription version has a little paper flap that gives the instructions..which the proposed over-the-counter version won't have. It would just be very clear on the box about the steps to use (the drug) and so I think that would be helpful," said Scott Weiner, an emergency medicine physician at Brigham and Women's Hospital ahead of the panel meeting.
An approval for OTC Narcan could increase its availability and align the federal government's stance with that of various states that have provisions to offer the drug without prescriptions through a pharmacist.
In support of the favorable vote, the American Medical Association said it believes "greater access will occur when naloxone for overdose risk is just as easily accessible in a pharmacy, grocery store and other common locations as a decongestant for a stuffy nose."
The FDA, which usually follows the recommendations of its expert panel but is not obligated to do so, is expected to make its final decision by March 29 on prescription-free sale of Narcan.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.